To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Preoperative human recombinant erythropoietin reduces allogenic blood transfusion

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
May 2013

Preoperative human recombinant erythropoietin reduces allogenic blood transfusion

Vol: 2| Issue: 4| Number:15| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty.

Int Orthop. 2012 Apr;36(4):703-9. Epub 2011 Oct 1.

Contributing Authors:
M Buljan D Nemet B Golubic-Cepulic G Bicanic B Tripkovic D Delimar

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

93 patients undergoing total hip arthroplasty were randomized to differing preoperative dosing regimes of human recombinant erythropoietin (rHu-EPO) to elucidate its affect on preoperative blood donation and intra-operative blood transfusions. Patients received either a once weekly i.v of 30000 IU rHu-EPO, a twice weekly i.v. of 15000 IU rHu-EPO, or no rHu-EPO. All groups received an oral does of ...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.